Merck & Co., Inc. vs iShares Semiconductor ETF — how do they compare? Merck & Co., Inc. trades at $133 (market cap $321.77B), while iShares Semiconductor ETF trades at $546.5. The key difference: Merck & Co., Inc. pays a 2.61% dividend while iShares Semiconductor ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| MRK | SOXX | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Sector/Thematic |
52-Week High | $131.84 | $655.01 |
52-Week Low | $77.60 | $241.68 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
SOXX trades at $552.56, up 4.24% with a bullish technical signal from moving averages. The semiconductor ETF faces mixed sentiment as recent news highlights sector rotation away from chips toward software, though major cloud companies' strong earnings support AI infrastructure demand. Technical indicators show neutral oscillators with key resistance at $548.
Outlook remains cautiously optimistic given AI-driven semiconductor demand, but risks include tariff impacts, concentration in 30 stocks, and potential overvaluation after 2026 gains. Institutional buying (Bank of America increased holdings 20.9% in Q1 2026) signals confidence, yet investor caution is warranted amid sector volatility.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →